Looking back on design software stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including PTC ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's ...

Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week ...

Welcoming back in-person delegates to its LiveWorx conference for the first time since the pre-pandemic days of 2019, and noting that the company finds itself in one of the greatest periods of change ...

PTC today announced it will demonstrate how Bobcat, a leading global manufacturer of compact equipment, can leverage the ...

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...

PTC announced the acquisition of the cloud-native computer-aided Manufacturing (CAM) solution, CloudMilling. Terms of the transaction were not disclosed. The UK-based father and son team, which had ...

I had a chance to speak with Jim Heppelmann, CEO of PTC (NASDQ: PTC), on the last snowy day of January 2019, about how his company is bringing AR and IoT technology solutions to thousands of ...